| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | August 15, 2025 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | August 15, 2025 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/10/2025 | $15.00 | Buy | Jefferies |
| 3/24/2025 | $7.00 → $10.00 | Buy | H.C. Wainwright |
| 12/31/2024 | $13.00 → $20.00 | Buy | BTIG Research |
| 9/30/2024 | $13.00 | Buy | Guggenheim |
| 11/21/2023 | $27.00 | Buy | BTIG Research |
| 9/27/2023 | $21.00 | Buy | B. Riley Securities |
| 6/15/2023 | $24.00 → $36.00 | Neutral → Buy | Mizuho |
| 9/7/2022 | $6.00 | Buy | Alliance Global Partners |
GFH375 demonstrated an overall response rate (ORR) of 68.8% in non-small cell lung cancer (NSCLC) at the recommended Phase 2 dose of 600 mg QD GFH375 demonstrated an ORR of 57.7% in efficacy evaluable patients with NSCLC across all dose levels Mini oral presentation on Sunday, September 7, 2025 from 12:00 to 1:15 pm (CEST) Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK-pathway-driven cancers, today announced positive, updated safety and efficacy data and late-breaking presentation details of partner GenFleet Therapeutics' Phase 1/2 study in China of GFH375, an oral KRAS G12D (ON/OFF) inhibitor, known as VS-7
Achieved AVMAPKI™ FAKZYNJA™ CO-PACK net product revenue of $2.1 million in the first six weeks of launch First patient dosed in the U.S. trial for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in KRAS G12D advanced solid tumors Ended Q2 2025 with $164.3 million in cash and cash equivalents; with product revenue and exercise of cash warrants, Company has expected cash runway into the second half of 2026 Company to host a conference call and webcast today at 4:30 p.m. ET Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business updates and reported financial results for
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its second quarter 2025 financial results and business updates on Thursday, August 7, 2025, at 4:30 pm ET. To access the conference call, please dial (800) 715-9871 (U.S.) or (646) 307-1963 (international) and enter the passcode 1210516 at least 10 minutes prior to the event start time. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, https://inv
EFFECT - Verastem, Inc. (0001526119) (Filer)
SCHEDULE 13G/A - Verastem, Inc. (0001526119) (Subject)
SCHEDULE 13G/A - Verastem, Inc. (0001526119) (Subject)
4 - Verastem, Inc. (0001526119) (Issuer)
4 - Verastem, Inc. (0001526119) (Issuer)
4 - Verastem, Inc. (0001526119) (Issuer)
4 - Verastem, Inc. (0001526119) (Issuer)
Jefferies initiated coverage of Verastem with a rating of Buy and set a new price target of $15.00
H.C. Wainwright reiterated coverage of Verastem with a rating of Buy and set a new price target of $10.00 from $7.00 previously
BTIG Research reiterated coverage of Verastem with a rating of Buy and set a new price target of $20.00 from $13.00 previously
Avutometinib plus defactinib granted priority review by FDA in December 2024, under the accelerated approval pathway, for KRAS mutant recurrent LGSOC; PDUFA action date set for June 30, 2025 Filed an investigational new drug application in the U.S. for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor RAMP 205 trial in 1L metastatic pancreatic cancer continues to progress with an additional dose cohort added and enrollment across all dose-level cohorts on track to complete in Q1 Company cash, cash equivalents, and investments of $88.8 million as of December 31, 2024; pro forma $151.3 million including debt refinancing and equity issuance with Oberland, and equity issuance under at-the-market
New executive leadership supports the company's transition to a fully integrated commercial-stage organization in a year of transformative growth with a potential new product launch in mid-2025. Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Matthew E. Ros as chief operating officer. In his role, Mr. Ros will report to Dan Paterson, president and chief executive officer, and will serve on the company's executive leadership team. "We are thrilled to welcome Matt to Verastem Oncology at an important time as we prepare for a mid-2025 product launch and th
Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the following leadership changes, effective immediately: John H. Johnson, a recognized leader in the pharmaceutical and biotechnology industry, has been named Executive Chairman;Dr. Shoshana Shendelman has stepped down as Chair and CEO; andLes Funtleyder, Applied Therapeutics' Chief Financial Officer, has been named Interim Chief Executive Officer. Mr. John
Achieved AVMAPKI™ FAKZYNJA™ CO-PACK net product revenue of $2.1 million in the first six weeks of launch First patient dosed in the U.S. trial for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in KRAS G12D advanced solid tumors Ended Q2 2025 with $164.3 million in cash and cash equivalents; with product revenue and exercise of cash warrants, Company has expected cash runway into the second half of 2026 Company to host a conference call and webcast today at 4:30 p.m. ET Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business updates and reported financial results for
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its second quarter 2025 financial results and business updates on Thursday, August 7, 2025, at 4:30 pm ET. To access the conference call, please dial (800) 715-9871 (U.S.) or (646) 307-1963 (international) and enter the passcode 1210516 at least 10 minutes prior to the event start time. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, https://inv
AVMAPKI plus FAKZYNJA to be commercially available by prescription as a convenient oral combination co-packaged together and will be known as "AVMAPKI FAKZYNJA CO-PACK" Accelerated approval, well ahead of the June 30, 2025 PDUFA action date, was based on the Phase 2 RAMP 201 study that demonstrated a 44% overall response rate in patients with KRAS mutant recurrent LGSOC Verastem to host investor conference call and webcast today at 2:30 pm ET Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Food and Drug Administration (FDA) has approved AVMAPKI™ FAKZYNJA™ CO-
SC 13G/A - Verastem, Inc. (0001526119) (Subject)
SC 13G/A - Verastem, Inc. (0001526119) (Subject)
SC 13G - Verastem, Inc. (0001526119) (Subject)